Komori
W

WAKAMOTO PHARMACEUTICAL CO.,LTD.

4512PharmaceuticalsMicro cap
300JPY+0.0%
★ Watch (sign-up required)
Price history
¥300Latest+4.5%
Drag across the chart to measure the move between two points.Delayed 15 minutes · monthly closing basis
Business overview

The Company’s business portfolio is centered on its pharmaceutical business, with a focus on ophthalmology, and also includes its healthcare and global businesses. In its pharmaceutical business, the Company manufactures and sells pharmaceuticals, medical devices and health foods in the ophthalmology field. In its healthcare business, the Company manufactures and sells its flagship product, Strong Wakimoto, as well as the AvanBeads series and FemCare products such as Femiflora. In its global business, the Company promotes the export of products including Strong Wakimoto and pharmaceutical ingredients, as well as new in-licensing and out-licensing activities, mainly in Asia, Europe, North America and Oceania. In Japan, it manufactures and sells products on a contract-manufacturing basis, diagnostic reagents and ingredients. Its real estate leasing business mainly comprises leasing related to COREDO Muromachi.

Recurring subjects
No threads yetThis company's filings have not been read yet. We are adding them progressively.
Companies sharing a theme
Loading
Documents
See all timely disclosuresSee all statutory filings
News
See all news
Key numbersShowing 8 of 20
PER
1,730.303How many years of earnings it would take to buy the stock. The market average is generally considered to be around 15.
PBR
0.89How many times the company's net assets? Around 1x is generally considered a benchmark.
ROE
0.1%Earning power. A figure above 10% is generally considered good.
Dividend yield
0.0%The annual dividend as a percentage of the share price.
Market capitalization
¥10bnShare price × number of shares. The value of the entire company.
Equity ratio
73.9%The proportion of assets funded by money that does not have to be repaid.
Operating margin
-5.6%The percentage of revenue remaining from the company’s core business.
Revenue growth (3 years)
9.2%The average annual growth in sales over the past three years.
What to watch next
Establishment of increased production capacity for products including Strong Wakamoto following the Sagami-Oi Plant capital investment plan, which began in March 2025 and is scheduled for completion in April 2026
Around April 2026Impact HighLikelihood Medium
Ophthalmology: monitor sales and adoption of AcrySof? Trinova Pro/Toric, launched in June 2025 and January 2026, respectively
Each quarter of FY2026Impact MediumLikelihood Medium
Ophthalmology: ramp-up of the contribution from the launch of MacuAid intravitreal injection 40 mg from February 2026 onward
From February 2026 onward, with the ramp-up to be assessed over the full fiscal yearImpact MediumLikelihood Medium
Pharmaceuticals: reassessment of sales fluctuations arising from drug price revisions and the institutional treatment of long-listed products, including the selected medical care system
Whenever the system is revised or its operation changes, with ongoing monitoring throughout the fiscal yearImpact HighLikelihood High
What to watch next
Loading
Who owns itTop holders total 58.8%
Listed holders 58.8%Everyone else 41.2%
ROHTO PHARMACEUTICAL CO.,LTD.11.44%
KISSEI PHARMACEUTICAL CO.,LTD.10.89%
AVI JAPAN OPPORTUNITY TRUST PLC8.64%
株式会社ブレストシーブ7.20%
わかもと製薬取引先持株会5.80%
Asahi Life Insurance Company3.47%
日本ゼトック株式会社3.46%
Mizuho Bank, Ltd.3.15%
2 other listed holders4.78%
Who owns it
HolderOwnership (%)
ROHTO PHARMACEUTICAL CO.,LTD.11.44
KISSEI PHARMACEUTICAL CO.,LTD.10.89
AVI JAPAN OPPORTUNITY TRUST PLC8.64
株式会社ブレストシーブ7.20
わかもと製薬取引先持株会5.80
Asahi Life Insurance Company3.47
日本ゼトック株式会社3.46
Mizuho Bank, Ltd.3.15
2 other listed holders4.78
This company's documents
Filings
Timely disclosures